Dexrazoxane monoHCl (formerly also known as ICRF-187, ADR-529) acts as an intracellular
iron chelator, which decreases the formation of superoxide radicals,
and is mainly used as a cardioprotective agent. As a derivative of EDTA,
dexrazoxane chelates iron, but the precise mechanism by which it
protects the heart is not known. This agent is used to protect the heart
against the cardiotoxic side effects. Dexrazoxane (10 mM), known
clinically to limit anthracycline cardiac toxicity, prevents
daunorubicin-induced myocyte apoptosis, but not necrosis induced by
higher anthracycline concentrations in rat cardiac myocytes.
纯度:≥98%
CAS:1263283-43-7